The health data analytics provider's series E round was co-led by Kaiser Permanente Group Trust at a $1bn valuation and also featured McKesson Ventures.

Lundbeckfonden Ventures and Chiesi Ventures have once again invested in the ocular oncology therapy developer, which has now raised $191m in total.

XtalPi and Astellas Venture Management contributed to a $45.6m round that took the drug discovery technology provider's total funding to over $60m.

Providence's health capacity management system has been spun off with $20m from investors including Providence Ventures and Kaiser Permanente Ventures

The McKesson-backed healthcare analytics software provider boosted its valuation to $3.3bn in a series E round that came just two months after its series D.

Novo and Lundbeck are in line for exits from the mitochondrial disease therapy developer, which has raised $145m across two funding rounds.

Lilly Asia Ventures co-led a $61.4m round for the antibody drug developer that will fund development of breast and gastric cancer drug candidates.

Eli Lilly has scored an exit after the inflammatory disease drug developer, which is now valued at about $1bn, went public.

SymBiosis and SIG-backed microbiome therapeutics developer Finch priced an upsized offering at the top of its range.

UCHealth contributed to a $15.5m round for the cardiovascular data platform developer that was led by Menlo Ventures.